Napoli 3-Ipsen (D-US-60010-001)

An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas 

The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for cancer therapy, namely 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for metastatic pancreatic cancer.

Locations: 

SIMR (Sacramento/Valley Area) Please contact Kirsten Babski at babskik@sutterhealth.org about study Napoli 3-Ipsen (D-US-60010-001)

Principal Investigator

Deepti Behl, MD

Co-Investigator(s)

Jasdeepa Nagi, M.D., Kristin N. Arreola, M.D., Brian K. Kim, M.D, Sivakumar Reddy, M.D. 

Recruitment Status

Active, Recruiting

Funder

Ipsen Bioscience

Start Date

September 09, 2020